Laboratory Medicine ›› 2022, Vol. 37 ›› Issue (12): 1151-1156.DOI: 10.3969/j.issn.1673-8640.2022.12.010
Previous Articles Next Articles
DENG Jie1, DENG Min2
Received:
2021-11-15
Revised:
2022-01-24
Online:
2022-12-30
Published:
2023-02-02
CLC Number:
DENG Jie, DENG Min. Roles of haptoglobin and ferritin in the prognostic assessment of colon cancer patients with liver metastasis[J]. Laboratory Medicine, 2022, 37(12): 1151-1156.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2022.12.010
项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | P值 |
---|---|---|---|---|---|
触珠蛋白 | 0.77(0.67~0.84) | 1.37 g/L | 70.3 | 77.8 | <0.001 |
铁蛋白 | 0.83(0.74~0.90) | 217.1 μg/L | 70.3 | 88.9 | <0.001 |
联合检测 | 0.87(0.78~0.93) | 82.4 | 88.9 | <0.001 |
项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | P值 |
---|---|---|---|---|---|
触珠蛋白 | 0.77(0.67~0.84) | 1.37 g/L | 70.3 | 77.8 | <0.001 |
铁蛋白 | 0.83(0.74~0.90) | 217.1 μg/L | 70.3 | 88.9 | <0.001 |
联合检测 | 0.87(0.78~0.93) | 82.4 | 88.9 | <0.001 |
组别 | 例数 | 年龄/岁 | 性别 | ECOG评分/ 分 | BMI/ (kg/m2) | 高血压/ [例(%)] | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
男/[例(%)] | 女/[例(%)] | ||||||||||
触珠蛋白≤1.37 g/L组 | 43 | 62.93±9.71 | 26(60.47) | 17(39.53) | 1(0,2) | 24.80±2.95 | 16(37.21) | ||||
触珠蛋白>1.37 g/L组 | 58 | 64.66±9.96 | 42(72.41) | 16(27.59) | 1(0,2) | 24.04±3.25 | 25(43.10) | ||||
统计值 | -0.87 | 1.60 | 0.64 | 1.21 | 0.36 | ||||||
P值 | 0.39 | 0.21 | 0.76 | 0.23 | 0.55 | ||||||
组别 | 糖尿病/ [例(%)] | 结肠癌根治术/[例(%)] | 化疗史/ [例(%)] | 分子靶向治疗史/[例(%)] | CRP/(mg/L) | CEA/(ng/mL) | |||||
触珠蛋白≤1.37 g/L组 | 7(16.28) | 16(37.21) | 36(83.72) | 17(39.53) | 9.90±5.81 | 13.89±8.76 | |||||
触珠蛋白>1.37 g/L组 | 17(29.31) | 16(27.59) | 48(82.76) | 28(48.28) | 13.43±9.10 | 18.16±9.57 | |||||
统计值 | 2.32 | 1.06 | 0.02 | 0.76 | -2.37 | -2.30 | |||||
P值 | 0.13 | 0.30 | 0.90 | 0.38 | 0.02 | 0.02 | |||||
组别 | CA 19-9/(U/mL) | Hb/(g/L) | Alb/(g/L) | ALT/(U/L) | AST/(U/L) | TB/(μmol/L) | |||||
触珠蛋白≤1.37 g/L组 | 58.27±23.85 | 113.95±21.76 | 34.65±5.42 | 59.32±31.77 | 67.65±27.28 | 52.73±27.69 | |||||
触珠蛋白>1.37 g/L组 | 57.31±19.96 | 109.59±23.26 | 33.87±4.47 | 67.90±27.87 | 81.41±28.33 | 61.78±29.31 | |||||
统计值 | 0.22 | 0.96 | 0.79 | -1.44 | -2.45 | -1.57 | |||||
P值 | 0.83 | 0.34 | 0.43 | 0.15 | 0.02 | 0.12 |
组别 | 例数 | 年龄/岁 | 性别 | ECOG评分/ 分 | BMI/ (kg/m2) | 高血压/ [例(%)] | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
男/[例(%)] | 女/[例(%)] | ||||||||||
触珠蛋白≤1.37 g/L组 | 43 | 62.93±9.71 | 26(60.47) | 17(39.53) | 1(0,2) | 24.80±2.95 | 16(37.21) | ||||
触珠蛋白>1.37 g/L组 | 58 | 64.66±9.96 | 42(72.41) | 16(27.59) | 1(0,2) | 24.04±3.25 | 25(43.10) | ||||
统计值 | -0.87 | 1.60 | 0.64 | 1.21 | 0.36 | ||||||
P值 | 0.39 | 0.21 | 0.76 | 0.23 | 0.55 | ||||||
组别 | 糖尿病/ [例(%)] | 结肠癌根治术/[例(%)] | 化疗史/ [例(%)] | 分子靶向治疗史/[例(%)] | CRP/(mg/L) | CEA/(ng/mL) | |||||
触珠蛋白≤1.37 g/L组 | 7(16.28) | 16(37.21) | 36(83.72) | 17(39.53) | 9.90±5.81 | 13.89±8.76 | |||||
触珠蛋白>1.37 g/L组 | 17(29.31) | 16(27.59) | 48(82.76) | 28(48.28) | 13.43±9.10 | 18.16±9.57 | |||||
统计值 | 2.32 | 1.06 | 0.02 | 0.76 | -2.37 | -2.30 | |||||
P值 | 0.13 | 0.30 | 0.90 | 0.38 | 0.02 | 0.02 | |||||
组别 | CA 19-9/(U/mL) | Hb/(g/L) | Alb/(g/L) | ALT/(U/L) | AST/(U/L) | TB/(μmol/L) | |||||
触珠蛋白≤1.37 g/L组 | 58.27±23.85 | 113.95±21.76 | 34.65±5.42 | 59.32±31.77 | 67.65±27.28 | 52.73±27.69 | |||||
触珠蛋白>1.37 g/L组 | 57.31±19.96 | 109.59±23.26 | 33.87±4.47 | 67.90±27.87 | 81.41±28.33 | 61.78±29.31 | |||||
统计值 | 0.22 | 0.96 | 0.79 | -1.44 | -2.45 | -1.57 | |||||
P值 | 0.83 | 0.34 | 0.43 | 0.15 | 0.02 | 0.12 |
组别 | 例数 | 年龄/岁 | 性别 | ECOG评分/ 分 | BMI/ (kg/m2) | 高血压/ [例(%)] | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男/[例(%)] | 女/[例(%)] | |||||||||||||||
铁蛋白≤217.1 μg/L组 | 46 | 61.20±10.55 | 28(60.87) | 18(39.13) | 1(0,1) | 24.03±3.25 | 20(43.48) | |||||||||
铁蛋白 >217.1 μg/L组 | 55 | 66.20±8.66 | 40(72.73) | 15(27.27) | 0(0,2) | 24.65±3.03 | 21(38.18) | |||||||||
统计值 | -2.61 | 1.60 | 0.54 | -0.99 | 0.29 | |||||||||||
P值 | 0.01 | 0.21 | 0.69 | 0.32 | 0.59 | |||||||||||
组别 | 糖尿病/ [例(%)] | 结肠癌根治术/[例(%)] | 化疗史/ [例(%)] | 分子靶向治疗史/[例(%)] | CRP/(mg/L) | CEA/(ng/mL) | ||||||||||
铁蛋白≤217.1 μg/L组 | 11(23.91) | 16(34.78) | 38(82.61) | 19(41.30) | 10.33±6.21 | 13.52±8.66 | ||||||||||
铁蛋白 >217.1 μg/L组 | 13(23.64) | 16(29.09) | 46(83.64) | 26(47.27) | 13.27±9.12 | 18.70±9.47 | ||||||||||
统计值 | 0.001 | 0.38 | 0.02 | 0.36 | -1.92 | -2.85 | ||||||||||
P值 | 0.97 | 0.54 | 0.89 | 0.55 | 0.06 | 0.005 | ||||||||||
组别 | CA 19-9/(U/mL) | Hb/(g/L) | Alb/(g/L) | ALT/(U/L) | AST/(U/L) | TB/(μmol/L) | ||||||||||
铁蛋白≤217.1 μg/L组 | 56.70±23.98 | 112.17±21.26 | 35.61±5.08 | 56.17±30.09 | 65.24±27.69 | 51.27±22.56 | ||||||||||
铁蛋白 >217.1 μg/L组 | 58.58±19.56 | 110.84±23.89 | 33.02±4.44 | 71.00±27.96 | 84.18±26.59 | 63.49±32.36 | ||||||||||
统计值 | -0.43 | 0.29 | 2.73 | -2.56 | -3.50 | -2.23 | ||||||||||
P值 | 0.67 | 0.77 | 0.007 | 0.01 | 0.001 | 0.03 |
组别 | 例数 | 年龄/岁 | 性别 | ECOG评分/ 分 | BMI/ (kg/m2) | 高血压/ [例(%)] | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男/[例(%)] | 女/[例(%)] | |||||||||||||||
铁蛋白≤217.1 μg/L组 | 46 | 61.20±10.55 | 28(60.87) | 18(39.13) | 1(0,1) | 24.03±3.25 | 20(43.48) | |||||||||
铁蛋白 >217.1 μg/L组 | 55 | 66.20±8.66 | 40(72.73) | 15(27.27) | 0(0,2) | 24.65±3.03 | 21(38.18) | |||||||||
统计值 | -2.61 | 1.60 | 0.54 | -0.99 | 0.29 | |||||||||||
P值 | 0.01 | 0.21 | 0.69 | 0.32 | 0.59 | |||||||||||
组别 | 糖尿病/ [例(%)] | 结肠癌根治术/[例(%)] | 化疗史/ [例(%)] | 分子靶向治疗史/[例(%)] | CRP/(mg/L) | CEA/(ng/mL) | ||||||||||
铁蛋白≤217.1 μg/L组 | 11(23.91) | 16(34.78) | 38(82.61) | 19(41.30) | 10.33±6.21 | 13.52±8.66 | ||||||||||
铁蛋白 >217.1 μg/L组 | 13(23.64) | 16(29.09) | 46(83.64) | 26(47.27) | 13.27±9.12 | 18.70±9.47 | ||||||||||
统计值 | 0.001 | 0.38 | 0.02 | 0.36 | -1.92 | -2.85 | ||||||||||
P值 | 0.97 | 0.54 | 0.89 | 0.55 | 0.06 | 0.005 | ||||||||||
组别 | CA 19-9/(U/mL) | Hb/(g/L) | Alb/(g/L) | ALT/(U/L) | AST/(U/L) | TB/(μmol/L) | ||||||||||
铁蛋白≤217.1 μg/L组 | 56.70±23.98 | 112.17±21.26 | 35.61±5.08 | 56.17±30.09 | 65.24±27.69 | 51.27±22.56 | ||||||||||
铁蛋白 >217.1 μg/L组 | 58.58±19.56 | 110.84±23.89 | 33.02±4.44 | 71.00±27.96 | 84.18±26.59 | 63.49±32.36 | ||||||||||
统计值 | -0.43 | 0.29 | 2.73 | -2.56 | -3.50 | -2.23 | ||||||||||
P值 | 0.67 | 0.77 | 0.007 | 0.01 | 0.001 | 0.03 |
项目 | 单因素分析 | 多因素分析 | |||
---|---|---|---|---|---|
HR值(95%CI) | P值 | HR值(95%CI) | P值 | ||
年龄(≥60岁与<60岁) | 1.08(0.65~1.76) | 0.78 | |||
性别(男与女) | 1.34(0.81~2.24) | 0.26 | |||
ECOG评分 | |||||
0分 | 参考变量 | 参考变量 | |||
1分 | 0.92(0.41~2.07) | 0.83 | |||
2分 | 1.25(0.50~3.15) | 0.64 | |||
3分 | 0.95(0.39~2.30) | 0.90 | |||
4分 | 2.35(1.28~6.58) | <0.001 | 1.99(1.38~10.64) | 0.02 | |
BMI | 1.00(0.93~1.08) | 0.96 | |||
高血压(有与无) | 1.14(0.71~1.81) | 0.59 | |||
糖尿病(有与无) | 1.10(0.64~1.87) | 0.74 | |||
结肠癌根治术(有与无) | 1.10(0.66~1.82) | 0.71 | |||
化疗史(有与无) | 0.75(0.43~1.31) | 0.31 | |||
分子靶向治疗史(有与无) | 1.27(0.80~2.01) | 0.31 | |||
CRP(>10.64 mg/L与≤10.64 mg/L) | 3.50(2.09~5.84) | <0.001 | 2.12(1.20~3.72) | 0.009 | |
CEA(>13.92 ng/mL与≤13.92 ng/mL) | 3.22(1.92~5.41) | <0.001 | 1.58(0.90~2.80) | 0.11 | |
CA19-9(>70.46 U/mL与≤70.46 U/mL) | 0.86(0.48~1.52) | 0.59 | |||
Hb(<110 g/L与≥110 g/L) | 0.79(0.50~1.25) | 0.31 | |||
Alb(<39.2 g/L与≥39.2 g/L) | 1.20(1.08~1.50) | 0.001 | 1.38(1.08~2.03) | 0.048 | |
ALT(>59 U/L与≤59 U/L) | 2.70(1.61~4.55) | <0.001 | 1.54(0.88~2.71) | 0.13 | |
AST(>54 U/L与≤54 U/L) | 3.10(1.59~6.06) | <0.001 | 1.53(0.69~3.41) | 0.29 | |
总胆红素(>39.2 mmol/L与≤39.2 mmol/L) | 1.09(0.66~1.79) | 0.44 | |||
触珠蛋白(>1.37 g/L与≤1.37 g/L) | 2.53(1.53~4.20) | <0.001 | 1.76(1.14~3.29) | 0.02 | |
铁蛋白(>217.1 μg/L与≤217.1 μg/L) | 3.34(1.98~5.65) | <0.001 | 1.70(1.07~2.94) | 0.04 |
项目 | 单因素分析 | 多因素分析 | |||
---|---|---|---|---|---|
HR值(95%CI) | P值 | HR值(95%CI) | P值 | ||
年龄(≥60岁与<60岁) | 1.08(0.65~1.76) | 0.78 | |||
性别(男与女) | 1.34(0.81~2.24) | 0.26 | |||
ECOG评分 | |||||
0分 | 参考变量 | 参考变量 | |||
1分 | 0.92(0.41~2.07) | 0.83 | |||
2分 | 1.25(0.50~3.15) | 0.64 | |||
3分 | 0.95(0.39~2.30) | 0.90 | |||
4分 | 2.35(1.28~6.58) | <0.001 | 1.99(1.38~10.64) | 0.02 | |
BMI | 1.00(0.93~1.08) | 0.96 | |||
高血压(有与无) | 1.14(0.71~1.81) | 0.59 | |||
糖尿病(有与无) | 1.10(0.64~1.87) | 0.74 | |||
结肠癌根治术(有与无) | 1.10(0.66~1.82) | 0.71 | |||
化疗史(有与无) | 0.75(0.43~1.31) | 0.31 | |||
分子靶向治疗史(有与无) | 1.27(0.80~2.01) | 0.31 | |||
CRP(>10.64 mg/L与≤10.64 mg/L) | 3.50(2.09~5.84) | <0.001 | 2.12(1.20~3.72) | 0.009 | |
CEA(>13.92 ng/mL与≤13.92 ng/mL) | 3.22(1.92~5.41) | <0.001 | 1.58(0.90~2.80) | 0.11 | |
CA19-9(>70.46 U/mL与≤70.46 U/mL) | 0.86(0.48~1.52) | 0.59 | |||
Hb(<110 g/L与≥110 g/L) | 0.79(0.50~1.25) | 0.31 | |||
Alb(<39.2 g/L与≥39.2 g/L) | 1.20(1.08~1.50) | 0.001 | 1.38(1.08~2.03) | 0.048 | |
ALT(>59 U/L与≤59 U/L) | 2.70(1.61~4.55) | <0.001 | 1.54(0.88~2.71) | 0.13 | |
AST(>54 U/L与≤54 U/L) | 3.10(1.59~6.06) | <0.001 | 1.53(0.69~3.41) | 0.29 | |
总胆红素(>39.2 mmol/L与≤39.2 mmol/L) | 1.09(0.66~1.79) | 0.44 | |||
触珠蛋白(>1.37 g/L与≤1.37 g/L) | 2.53(1.53~4.20) | <0.001 | 1.76(1.14~3.29) | 0.02 | |
铁蛋白(>217.1 μg/L与≤217.1 μg/L) | 3.34(1.98~5.65) | <0.001 | 1.70(1.07~2.94) | 0.04 |
1 | VALDERRAMA-TREVIÑO A I, BARRERA-MERA B, CEBALLOS-VILLALVA J C, et al. Hepatic metastasis from colorectal cancer[J]. Euroasian J Hepatogastroenterol, 2017, 7(2):166-175. |
2 |
PADMANABHAN C, NUSSBAUM D P, D'ANGELICA M. Surgical management of colorectal cancer liver metastases[J]. Surg Oncol Clin N Am, 2021, 30(1):1-25.
DOI PMID |
3 |
KUAI L, ZHANG Y, LUO Y, et al. Prognostic nomogram for liver metastatic colon cancer based on histological type,tumor differentiation,and tumor deposit:a TRIPOD compliant large-scale survival study[J]. Front Oncol, 2021, 11:604882.
DOI URL |
4 | 叶青, 朱建勇, 张立波, 等. 血清白细胞介素-6、触珠蛋白及淀粉样蛋白A对慢性阻塞性肺疾病患者肺部感染的鉴别诊断研究[J]. 中华医院感染学杂志, 2017, 27(13):2961-2964. |
5 |
MORISHITA K, ITO N, KODA S, et al. Haptoglobin phenotype is a critical factor in the use of fucosylated haptoglobin for pancreatic cancer diagnosis[J]. Clin Chim Acta, 2018, 487:84-89.
DOI PMID |
6 |
FUJITA K, SHIMOMURA M, UEMURA M, et al. Serum fucosylated haptoglobin as a novel prognostic biomarker predicting high-Gleason prostate cancer[J]. Prostate, 2014, 74(10):1052-1058.
DOI PMID |
7 |
BROWN R A M, RICHARDSON K L, KABIR T D, et al. Altered iron metabolism and impact in cancer biology,metastasis,and immunology[J]. Front Oncol, 2020, 10:476.
DOI URL |
8 |
CHIBAUDEL B, MAINDRAULT-GOEBEL F, LLEDO G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study[J]. J Clin Oncol, 2009, 27(34):5727-5733.
DOI PMID |
9 |
FENG Z, CHEN J W, FENG J H, et al. The association between serum ferritin with colorectal cancer[J]. Int J Clin Exp Med, 2015, 8(12):22293-22299.
PMID |
10 |
GIESSEN-JUNG C, NAGEL D, GLAS M, et al. Preoperative serum markers for individual patient prognosis in stage Ⅰ-Ⅲ colon cancer[J]. Tumour Biol, 2015, 36(10):7897-7906.
DOI URL |
11 |
LI F, KISHIDA T, KOBAYASHI M. Serum iron and ferritin levels in patients with colorectal cancer in relation to the size,site,and disease stage of cancer[J]. J Gastroenterol, 1999, 34(2):195-199.
DOI URL |
12 |
LEE S, SONG A, EO W. Serum ferritin as a prognostic biomarker for survival in relapsed or refractory metastatic colorectal cancer[J]. J Cancer, 2016, 7(8):957-964.
DOI PMID |
13 |
SUN L, PAN J, PENG L, et al. Combination of haptoglobin and osteopontin could predict colorectal cancer hepatic metastasis[J]. Ann Surg Oncol, 2012, 19(7):2411-2419.
DOI PMID |
14 |
SUN L, HU S, YU L, et al. Serum haptoglobin as a novel molecular biomarker predicting colorectal cancer hepatic metastasis[J]. Int J Cancer, 2016, 138(11):2724-2731.
DOI PMID |
15 | 蒋志强, 李亚兰, 韩广森, 等. 术前血清白蛋白水平与结肠癌临床病理特征及生存预后的关系[J]. 中华胃肠外科杂志, 2016, 19(1):80-83. |
16 |
HAMILTON T D, LEUGNER D, KOPCIUK K, et al. Identification of prognostic inflammatory factors in colorectal liver metastases[J]. BMC Cancer, 2014, 14:542.
DOI PMID |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||